What Is Zepbound (Tirzepatide)?
Zepbound is an FDA-approved weight loss injection developed by Eli Lilly. It is the first and only approved medication that activates both the GIP and GLP-1 receptors at the same time. That dual mechanism is what sets it apart from semaglutide-based medications like Wegovy and Ozempic, which work on GLP-1 alone. By targeting two hormonal pathways instead of one, Zepbound produces greater appetite suppression and more weight loss than any other currently approved medication.
How the Dual GIP/GLP-1 Mechanism Works
GIP Receptor ActivationGIP acts on fat cells and the brain to reduce appetite and improve fat metabolism. Researchers believe this is the key reason tirzepatide outperforms GLP-1-only medications in head-to-head trials.
GLP-1 Receptor ActivationGLP-1 signals fullness to the brain, slows stomach emptying so you feel satisfied longer, and helps regulate blood sugar after meals. These are the same benefits you get from Wegovy and Ozempic.
Who Qualifies for Zepbound?
Zepbound is indicated for adults with a BMI of 30 or above, or those with a BMI of 27 or above who have at least one weight-related medical condition such as high blood pressure, type 2 diabetes, high cholesterol, obstructive sleep apnea, or cardiovascular disease. A licensed Vitercure clinician will review your full medical history before any prescription is issued.
Zepbound vs Mounjaro: Same Drug, Different Approvals
Both Zepbound and Mounjaro contain tirzepatide. Mounjaro is approved for blood sugar control in type 2 diabetes, while Zepbound is approved for chronic weight management. The active ingredient is the same, the dosing is similar, but the FDA indication is different. Your clinician will determine the most appropriate brand based on your diagnosis and insurance.
Zepbound Weight Loss Results (SURMOUNT Trial Data)
The SURMOUNT trial program is the largest and most rigorous tirzepatide weight loss dataset. The primary trial, SURMOUNT-1, enrolled 2,539 adults over 72 weeks.
| Dose | Avg Weight Loss | Lost 5%+ | Lost 15%+ | Lost 20%+ |
|---|
| Placebo | 2.4% | 35% | 9% | 5% |
| 5mg | 16.0% | 85% | 49% | 30% |
| 10mg | 20.9% | 89% | 67% | 51% |
| 15mg (max) | 22.5% | 96% | 77% | 63% |
SURMOUNT-5: Zepbound vs Wegovy Head-to-Head
In the first direct comparison between tirzepatide and semaglutide 2.4mg (Wegovy), patients on Zepbound lost roughly twice as much body weight (about 20% vs about 13%). This confirmed what the separate trials had suggested and established Zepbound as the highest-efficacy FDA-approved weight loss injection currently available.
How to Use Zepbound
Administration Basics
- Form: Pre-filled multi-dose pen (4 weekly doses per pen).
- Frequency: Once weekly, same day each week.
- Injection sites: Abdomen, thigh, or upper arm. Rotate sites.
- Timing: Any time of day, with or without food.
- Storage: Refrigerate at 36 to 46 degrees F (2 to 8 degrees C). Cold-chain shipping preserves potency.
Zepbound Dose Escalation Schedule
| Period | Weekly Dose | Purpose |
|---|
| Weeks 1 to 4 | 2.5mg | Starting dose to help your body adjust. GI effects typically peak here. |
| Weeks 5 to 8 | 5mg | First therapeutic step up if tolerated. |
| Weeks 9 to 16 | 7.5mg | Mid-range dose. SURMOUNT-1 showed meaningful weight loss here. |
| Weeks 17 to 24 | 10mg | 20.9% average body weight loss at 72 weeks in SURMOUNT-1. |
| Weeks 25 to 32 | 12.5mg | Higher dose for patients who need and tolerate more. |
| Week 33 onward | 15mg | Maximum dose. 22.5% average body weight loss in SURMOUNT-1. |
Zepbound vs Wegovy vs Ozempic: Key Differences
These are the three injectable GLP-1 based weight loss medications most commonly compared. Here is how they differ in mechanism, outcomes, and dosing.
| Feature | Zepbound | Wegovy | Ozempic |
|---|
| Mechanism | Dual GIP + GLP-1 | GLP-1 only | GLP-1 only |
| Weight loss FDA approval | Yes (Zepbound) | Yes (Wegovy) | No (off-label) |
| Avg weight loss | 22.5% (SURMOUNT-1, 72 wk) | 15.3% (STEP-1, 68 wk) | 6 to 9% (SUSTAIN, 30 wk) |
| Lost 20%+ | 63% at 15mg | about 30% at 2.4mg | Not indicated |
| Max dose | 15mg/week | 2.4mg/week | 2mg/week |
| CV outcomes trial | SURMOUNT-MMO (ongoing) | SELECT (20% reduction) | SUSTAIN-6 (26% reduction) |
Your prescriber will evaluate your full health picture before recommending a specific medication.
Important Safety Information for Zepbound
This is not a complete list of warnings or side effects. Always review the full Prescribing Information and Medication Guide, and speak with a licensed clinician.
Boxed Warning: Thyroid C-Cell Tumors
Do not use Zepbound if you or a family member has a history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Contact your clinician if you notice a neck lump, trouble swallowing, hoarseness, or shortness of breath.
Other Serious Risks
Serious risks include pancreatitis, gallbladder problems, low blood sugar (especially with diabetes medications), kidney injury, and allergic reactions. Seek urgent care for severe abdominal pain, signs of allergic reaction, or any symptom that concerns you.
Common Side Effects
The most common side effects are nausea, vomiting, diarrhea, constipation, decreased appetite, and stomach discomfort. These are usually worst during dose escalation and tend to improve as your body adjusts. Slow, gradual titration as supervised by your clinician is the main strategy for minimizing GI effects.
Frequently Asked Questions About Zepbound
In the SURMOUNT-1 trial (2,539 participants, 72 weeks), patients on tirzepatide 15mg lost an average of 22.5% of their body weight, compared to 2.4% on placebo. At the 15mg dose, 63% of participants lost 20% or more and 96% lost at least 5%. At 10mg, average loss was 20.9%. At 5mg, it was 16.0%. Your individual results will depend on your dose, adherence, diet, exercise, and other health factors.
The SURMOUNT-5 head-to-head trial showed that tirzepatide (Zepbound) produced roughly twice as much weight loss as semaglutide 2.4mg (Wegovy) in patients with obesity or overweight without type 2 diabetes. The dual GIP/GLP-1 mechanism likely accounts for this difference. That said, the "better" choice depends on your individual situation. Your clinician will consider your medical history, tolerability, insurance coverage, and goals before recommending a specific medication.
Zepbound is FDA-approved for chronic weight management in adults with a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related medical condition such as high blood pressure, type 2 diabetes, high cholesterol, or sleep apnea. It is used alongside a reduced-calorie diet and increased physical activity.
Both Zepbound and Mounjaro contain tirzepatide, the exact same active ingredient. The difference is the FDA indication: Zepbound is approved specifically for chronic weight management, while Mounjaro is approved for blood sugar control in type 2 diabetes. The dosing schedules are similar. Your prescriber determines which brand is appropriate based on your diagnosis, goals, and insurance.
Yes. Through Vitercure, eligible adults can complete a brief online health questionnaire, consult with a licensed clinician through our HIPAA-compliant telehealth platform, and if appropriate, receive a Zepbound prescription fulfilled by licensed US partner pharmacies with cold-chain shipping. A valid prescription is required.
PCOS is associated with insulin resistance, elevated androgens, and obesity, all areas where tirzepatide may be beneficial. While Zepbound is not specifically FDA-approved for PCOS, its dual GIP/GLP-1 mechanism targets insulin resistance directly, and growing clinical evidence suggests it may help patients with PCOS-related weight challenges. Your Vitercure clinician will assess whether Zepbound is appropriate for your situation.
Zepbound is designed for chronic weight management, not short-term use. The SURMOUNT-1 data at 72 weeks showed continued benefits, and the SURMOUNT-4 trial showed that stopping leads to weight regain in most patients. Many people remain on Zepbound long-term as part of ongoing metabolic care. Your clinician will periodically reassess your progress and goals.
The SURMOUNT-4 trial showed that patients who stopped tirzepatide after 36 weeks gradually regained most of the weight they had lost within about a year. Appetite and food cravings typically return. You should never stop Zepbound without talking to your clinician first, so they can help plan a transition or alternative strategy.
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, and stomach discomfort. These are usually worst during dose escalation and tend to improve as your body adjusts. Serious but rare risks include pancreatitis, gallbladder problems, kidney injury, low blood sugar (with diabetes medications), and allergic reactions. Zepbound carries a boxed warning for possible thyroid C-cell tumors and is not for patients with a personal or family history of MTC or MEN 2.
